Supernus Pharmaceuticals (FRA:S49) Accounts Payable : €13.2 Mil (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Supernus Pharmaceuticals Accounts Payable?

Supernus Pharmaceuticals's Accounts Payable for the quarter that ended in Mar. 2024 was €13.2 Mil.

Supernus Pharmaceuticals's quarterly Accounts Payable declined from Sep. 2023 (€3.2 Mil) to Dec. 2023 (€1.8 Mil) but then increased from Dec. 2023 (€1.8 Mil) to Mar. 2024 (€13.2 Mil).

Supernus Pharmaceuticals's annual Accounts Payable increased from Dec. 2021 (€8.3 Mil) to Dec. 2022 (€10.0 Mil) but then declined from Dec. 2022 (€10.0 Mil) to Dec. 2023 (€1.8 Mil).

Supernus Pharmaceuticals Accounts Payable Historical Data

The historical data trend for Supernus Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Supernus Pharmaceuticals Accounts Payable Chart

Supernus Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable

Get a 7-Day Free Trial

9.13

5.05

8.26

9.95

1.80

Supernus Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable	Get a 7-Day Free Trial															10.78	4.06	3.18	1.80	13.25

Supernus Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Supernus Pharmaceuticals Accounts Payable Related Terms

Thank you for viewing the detailed overview of Supernus Pharmaceuticals's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Supernus Pharmaceuticals (FRA:S49) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Supernus Pharmaceuticals Inc (FRA:S49) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

SUPN:USA S49:Germany

Address

9715 Key West Avenue, Rockville, MD, USA, 20850

Website

https://www.supernus.com

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Supernus Pharmaceuticals (FRA:S49) Headlines

No Headlines